Work

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps3087

Authors: Omid Hamid, Laura Quan Man Chow, Fatemeh Tavakkoli, Shannon Marshall, Matthew Joseph Gribbin, Joyson Joseph Karakunnel, Jhanelle Elaine Gray

Institutions: Angeles Clinic and Research Institute, University of Washington, Moffitt Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2525143531

Cites:

Cited by: 7

Related to: 10